Erlanger B F
Dept of Microbiology, Columbia University Health Sciences Center, New York, NY 10032.
Immunol Today. 1992 Dec;13(12):487-90. doi: 10.1016/0167-5699(92)90023-Z.
The site and mode of action of cyclosporin A (CsA) have been subjects of study ever since CsA was discovered and demonstrated to be a selective suppressor of allograft rejection. In this article, Bernard Erlanger traces progress to date and presents evidence that the site of action is not cytoplasmic cyclophilin but a lymphocyte cell-surface receptor that might be related in structure to cyclophilin.
自从环孢素A(CsA)被发现并被证明是同种异体移植排斥反应的选择性抑制剂以来,其作用部位和作用方式一直是研究的课题。在本文中,伯纳德·埃尔朗热追溯了迄今为止的研究进展,并提出证据表明其作用部位不是细胞质亲环蛋白,而是一种淋巴细胞细胞表面受体,其结构可能与亲环蛋白有关。